Cuál es el precio por Harpoon Therapeutics, Inc. (HARP)

Precio por Harpoon Therapeutics, Inc. (HARP) es de$23.01

Cuál es la capitalización de mercado por Harpoon Therapeutics, Inc. (HARP)

Capitalización de mercado por Harpoon Therapeutics, Inc. (HARP) es $74.80M

Harpoon Therapeutics, Inc. (HARP) EPS

Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States. The company's innovative Tri-specific T cell activating construct (TriTAC) platform forms the basis of its development pipeline. This includes HPN328, currently undergoing Phase I/II clinical trials for small cell lung cancer and tumors that express Delta-like canonical Notch ligand 3; HPN217, also in Phase I/II trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical evaluation for ovarian and pancreatic cancers, alongside other mesothelin-expressing tumors. Furthermore, Harpoon has a preclinical asset, HPN601, aimed at various solid tumor indications. The company has also established a discovery collaboration and licensing agreement with AbbVie Biotechnology Ltd. to develop and market products combining its unique TriTAC technology with soluble T cell receptors. Founded in 2015, Harpoon Therapeutics, Inc. is headquartered in South San Francisco, California.

Año	EPS	Cambiar
Not enough data for the provided dates.

Año

EPS

Cambiar

Not enough data for the provided dates.

Empresa	EPS	Diferencia de EPS	País
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Moderna, Inc. MRNA.US	$-7.98	-	US
CSL Limited CSL.AX	$-5.29	-	AU
Lonza Group AG LONN.SW	-	-	CH

Empresa

EPS

Diferencia de EPS

País